Huazhi Rougan Granule
Helicobacter Pylori Infection, Susceptibility To
Explore 2 assets in Helicobacter Pylori Infection, Susceptibility To →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Nanjing First Hospital, Nanjing Medical University
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07159412CT.gov Huazhi Rougan Granule as an Add-On Therapy for H. Pylori Infection With Metabolic-associated Steatohepatitis | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Helicobacter Pylori Infection, Susceptibility To
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Huazhi Rougan Granule (this asset) | Nanjing First Hospital, Nanjing Medical University | N/A | D · 30 |
| Bismuth Salicylate | Fatih Sultan Mehmet Training and Research Hospital | P4 | BB |
| Orelabrutinib | Fudan University | P2 | CCC |
Other indications for Huazhi Rougan Granule
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | N/A | D · 30 |
| Liver Disorder | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Huazhi Rougan Granule in Helicobacter Pylori Infection, Susceptibility To. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/huazhi-rougan-granule-helicobacter-pylori-infection-susceptibility-to
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →